Gene therapy for ovarian cancer fails PhIII study — sinking biotech's shares
Despite promising interim results, VBL Therapeutics’ ovarian cancer drug has ultimately flopped in a Phase III trial.
The Nasdaq-listed Israeli biotech revealed that the OVAL trial of ofranergene obadenovec (also known as ofra-vec, or VB-111) did not meet the primary endpoints of improving upon progression-free survival or overall survival.
“Based on this outcome, we plan to discontinue the OVAL trial and will review the data from our ongoing Phase 2 trials in metastatic colorectal cancer and recurrent glioblastoma multiforme to determine next steps with the ofra-vec program,” CEO Dror Harats said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.